Histone Demethylase KDM5B as a Therapeutic Target for Cancer Therapy

Jose, Anmi and Shenoy, Gautham G and Rodrigues, Sunil Gabriel and Kumar, Naveena AN and Munisamy, Murali and Thomas, Levin and Rao, Mahadev (2020) Histone Demethylase KDM5B as a Therapeutic Target for Cancer Therapy. Cancers, 12 (8). pp. 1-16. ISSN 2072-6694

[img] PDF
9431 DisplayPdf.pdf - Published Version
Restricted to Registered users only

Download (3MB) | Request a copy


Lysine-specific demethylase 5B (KDM5B/PLU1/JARID1B) is found to be overexpressed in numerous malignancies, including breast, lung, skin, liver, and prostate cancer. Identification of molecules targeting the KDM5B enzyme could be a potential lead in cancer research. Although many KDM5B inhibitors with promising outcomes have been developed so far, its further application in clinical practice is limited due to toxicity and lack of target specificity. Here, we summarize the significance of targeting KDM5B in anticancer therapy and report the molecular docking studies of some known anti-viral agents, decitabine, entecavir, abacavir, penciclovir, and 3-deazaneplanocin A in the catalytic domain JmjC of KDM5B. These studies show the repurposing potential of identified anti-viral agents in cancer therapy

Item Type: Article
Uncontrolled Keywords: Cancer; Histone modification; Inhibitor; KDM5B; Molecular docking; Repurposing
Subjects: Pharmacy > MCOPS Manipal > Pharmaceutical Chemistry
Pharmacy > MCOPS Manipal > Pharmacy Practice
Medicine > KMC Manipal > Surgery
Medicine > KMC Manipal > Surgical Oncology
Depositing User: KMC Library
Date Deposited: 15 Oct 2020 04:24
Last Modified: 15 Oct 2020 04:24
URI: http://eprints.manipal.edu/id/eprint/155882

Actions (login required)

View Item View Item